Unlike traditional approaches, Immunethep's vaccine doesn't kill bacteria. Instead, it neutralizes a virulence mechanism bacteria use to shut down the immune system. This restores the body's natural ability to fight infection, a novel strategy analogous to checkpoint inhibitors in oncology.

The rationale for "virus hunting" is to create advance vaccines. However, you cannot safely test a vaccine for a novel, deadly pathogen on healthy humans. This makes the knowledge unactionable for prevention, while creating immense risk by bringing dangerous pathogens into leaky labs and publicizing their existence.

Effective vaccines eradicate the visible horror of diseases. By eliminating the pain and tragic outcomes from public memory, vaccines work against their own acceptance. People cannot fear what they have never seen, leading to complacency and vaccine hesitancy because the terrifying counterfactual is unimaginable.

Unlike a drug that can be synthesized to a chemical standard, most vaccines are living biological products. This means the entire manufacturing process must be perfectly managed and cannot be altered without re-validation. This biological complexity makes production far more difficult and expensive than typical pharmaceuticals.

Evolutionary modeling shows that taking antibiotics beyond symptom resolution can be counterproductive. It needlessly kills off susceptible bacteria, creating a perfect environment for resistant strains to flourish. The optimal strategy is often to stop once the immune system can handle the rest, contrary to decades of medical advice.

Investors are hesitant to fund antimicrobial resistance research because the field has been stuck for decades trying the same approaches—traditional antibiotics and vaccines—and expecting different results. A fundamental shift in scientific strategy is required to regain investor confidence and make progress against superbugs.

The FDA is shifting policy to no longer allow reliance on immunogenicity data (immunobridging) for approving new or updated vaccines. This move toward requiring full clinical efficacy trials will make it harder to combat evolving pathogens and would have prevented past approvals of key vaccines like those for HPV and Ebola.

When a public health intervention successfully prevents a crisis, the lack of a negative outcome makes the initial action seem like an unnecessary overreaction. This paradox makes it difficult to justify and maintain funding for preventative measures whose success is invisible.

Taking an antibiotic acts as a natural selection event. It kills susceptible bacteria, but the single microbe that survives due to natural resistance will rapidly repopulate, creating a new, fully resistant colony. This process occurs every time an antibiotic is used.